Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more.
The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Viral Vectors Engineered for Gene TherapyKenneth Lundstrom
2. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity
Noelia Silva-Pilipich, ?ngela Covo-Vergara, Luc?a Vanrell, and Cristian Smerdou
3. Armored modified vaccinia Ankara in cancer immunotherapy
Cigdem Atay, Jos? Medina-Echeverz, Hubertus Hochrein, Mark Suter, and Maria Hinterberger
4. Alphaviruses in Cancer Immunotherapy
Kenneth Lundstrom
5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success
Irati Herv?s-Corpi?n and Marta M. Alonso
6. Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies
M?rio Sousa-Pimenta, ?ngelo Martins, and Vera Machado
7. Oncolytic virotherapy in lung cancer
Estanislao Nistal-Villan, Sergio Rius-Rocabert, and Francisco Llinares-Pinel
8. Rational selection of an ideal oncolytic virus to address current limitations in clinical translation
Rupsa Basu and Chad M. Moles
